<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002515</url>
  </required_header>
  <id_info>
    <org_study_id>92-148</org_study_id>
    <secondary_id>CDR0000078115</secondary_id>
    <secondary_id>NCI-V93-0214</secondary_id>
    <nct_id>NCT00002515</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer</brief_title>
  <official_title>Myeloablative Chemotherapy With Bone Marrow Rescue For Rare Poor-Prognosis Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Bone marrow transplantation may allow doctors to give higher doses&#xD;
      of chemotherapy and kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy with thiotepa,&#xD;
      carboplatin, and topotecan followed by bone marrow transplantation in treating patients who&#xD;
      have metastatic or progressive rare cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Improve the long term disease-free survival of patients with rare cancers at high risk&#xD;
           for lethal relapse by using myeloablative chemotherapy with thiotepa, carboplatin, and&#xD;
           topotecan followed by autologous bone marrow or peripheral blood stem cell rescue.&#xD;
&#xD;
      OUTLINE: Autologous bone marrow or peripheral blood stem cells (PBSC) are harvested. Patients&#xD;
      receive high-dose thiotepa IV over 3 hours on days -8 to -6, carboplatin IV over 4 hours on&#xD;
      days -5 to -3, and topotecan IV over 30 minutes on days -8 to -4. Autologous bone marrow or&#xD;
      PBSC are reinfused on day 0. Patients receive filgrastim (G-CSF) IV twice daily beginning on&#xD;
      day 1.&#xD;
&#xD;
      Patients are followed for 1 year.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 50 patients will be accrued for this study within 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 1992</start_date>
  <completion_date type="Actual">April 2005</completion_date>
  <primary_completion_date type="Actual">April 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Childhood Germ Cell Tumor</condition>
  <condition>Extragonadal Germ Cell Tumor</condition>
  <condition>Head and Neck Cancer</condition>
  <condition>Kidney Cancer</condition>
  <condition>Liver Cancer</condition>
  <condition>Lymphoma</condition>
  <condition>Neuroblastoma</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Retinoblastoma</condition>
  <condition>Sarcoma</condition>
  <condition>Testicular Germ Cell Tumor</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thiotepa</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>topotecan hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>autologous bone marrow transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>bone marrow ablation with stem cell support</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>in vitro-treated bone marrow transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed malignancy of one of the following types:&#xD;
&#xD;
               -  Wilms' tumor&#xD;
&#xD;
               -  Liver cancer&#xD;
&#xD;
               -  Desmoplastic or other small round cell tumor&#xD;
&#xD;
               -  Nasopharyngeal carcinoma&#xD;
&#xD;
               -  Fibrosarcoma&#xD;
&#xD;
          -  Disease that has metastasized and has a cure rate of no greater than 25% with&#xD;
             conventional treatment or disease that has progressed after prior chemotherapy, was&#xD;
             not then surgically resectable, and has a salvage rate with nonmyeloablative therapies&#xD;
             of no greater than 25% required&#xD;
&#xD;
          -  Maximal benefit from conventional (nonmyeloablative) doses of combination chemotherapy&#xD;
             required prior to entry, and it is recommended that patients have received a minimum&#xD;
             of one of the following:&#xD;
&#xD;
               -  2 courses of high-dose cyclophosphamide (as per protocol MSKCC-90062)&#xD;
&#xD;
               -  2 courses of high-dose ifosfamide/etoposide (as in the poor-risk sarcoma protocol&#xD;
                  MSKCC-90071A)&#xD;
&#xD;
               -  1 course of high-dose cyclophosphamide plus 1 course of high-dose&#xD;
                  ifosfamide/etoposide&#xD;
&#xD;
          -  Within 3 weeks of initiation of protocol therapy, patients must be:&#xD;
&#xD;
               -  In CR or good PR OR&#xD;
&#xD;
               -  Tumor considered &quot;chemosensitive&quot;, i.e., a 50% or greater decrease in at least 1&#xD;
                  measurable tumor parameter attributable to prior chemotherapy without evidence of&#xD;
                  progressive disease by any other parameter&#xD;
&#xD;
          -  Ineligible for other IRB-approved myeloablative regimens&#xD;
&#xD;
          -  No evidence of current bone marrow involvement on bone marrow aspiration (x4) and&#xD;
             biopsy (x2)&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  21 and under&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  SGOT no greater than 1.5 times ULN&#xD;
&#xD;
          -  Alkaline phosphatase no greater than 1.5 times ULN&#xD;
&#xD;
          -  5'-Nucleotidase no greater than 1.5 times ULN&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine normal&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  CPK normal&#xD;
&#xD;
          -  Echocardiogram (or RNCA) normal&#xD;
&#xD;
          -  EKG normal&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian H. Kushner, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 20, 2013</last_update_submitted>
  <last_update_submitted_qc>June 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2013</last_update_posted>
  <keyword>chondrosarcoma</keyword>
  <keyword>recurrent childhood rhabdomyosarcoma</keyword>
  <keyword>stage IV childhood liver cancer</keyword>
  <keyword>recurrent neuroblastoma</keyword>
  <keyword>recurrent childhood liver cancer</keyword>
  <keyword>recurrent Wilms tumor and other childhood kidney tumors</keyword>
  <keyword>stage IV Wilms tumor</keyword>
  <keyword>recurrent retinoblastoma</keyword>
  <keyword>stage IV childhood lymphoblastic lymphoma</keyword>
  <keyword>recurrent childhood lymphoblastic lymphoma</keyword>
  <keyword>recurrent osteosarcoma</keyword>
  <keyword>stage IV ovarian germ cell tumor</keyword>
  <keyword>recurrent malignant testicular germ cell tumor</keyword>
  <keyword>childhood germ cell tumor</keyword>
  <keyword>alveolar childhood rhabdomyosarcoma</keyword>
  <keyword>recurrent childhood soft tissue sarcoma</keyword>
  <keyword>recurrent ovarian germ cell tumor</keyword>
  <keyword>childhood fibrosarcoma</keyword>
  <keyword>extragonadal germ cell tumor</keyword>
  <keyword>childhood desmoplastic small round cell tumor</keyword>
  <keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
  <keyword>stage IV childhood small noncleaved cell lymphoma</keyword>
  <keyword>recurrent childhood large cell lymphoma</keyword>
  <keyword>stage IV childhood large cell lymphoma</keyword>
  <keyword>recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
  <keyword>stage IV lymphoepithelioma of the nasopharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>recurrent lymphoepithelioma of the nasopharynx</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
    <mesh_term>Neuroblastoma</mesh_term>
    <mesh_term>Neoplasms, Germ Cell and Embryonal</mesh_term>
    <mesh_term>Retinoblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Topotecan</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

